TauRx Therapeutics
15 articles about TauRx Therapeutics
-
TauRx Reveals Study Results That Offers New Hope for Treatment of Patients With Dementia
5/19/2020
Minimum dose of hydromethylthionine could slow clinical decline and brain atrophy in behavioural variant Fronto-Temporal Dementia as well as Alzheimer's Disease
-
New Study by TauRx Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer's Disease
11/26/2019
These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy.
-
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
-
TauRx Therapeutics' Second Phase III Study Results for LMTX Published in the Journal of Alzheimer...
11/27/2017
The results of the earlier study showed significant differences in favour of two higher doses of LMTX when taken as monotherapy compared with the intended 4 mg control dose taken as monotherapy or as add-on therapy to currently approved treatments for Alzheimer's disease in pre-specified post hoc... -
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease
1/20/2015
-
MediciGlobal Supports TauRx Therapeutics Sponsorship Of "Meet The Experts" Event At International Conference On Frontotemporal Dementias
10/24/2014
-
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease
9/22/2014
-
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease
7/17/2014
-
TauRx Therapeutics Expands Alzheimer's Clinical Trials In The United States
1/6/2014
-
TauRx Therapeutics Achieves Milestone in Global Phase 3 Clinical Trials of LMTX™ for Alzheimer's Disease
9/20/2013
-
TauRx Therapeutics Release: First UK Patients Enroll in Phase 3 Clinical Trials of LMTX for Alzheimer's Disease
5/23/2013
-
TauRx Therapeutics Release: New Thinking Needed for an Age-Old Disease
11/8/2012
-
TauRx Therapeutics Selects BioClinica, Inc. for eClinical and Imaging Solutions
11/5/2012
-
TauRx Therapeutics Release: Phase 3 Clinical Trial Begins in Early Form of Dementia
9/10/2012
-
TauRx Therapeutics Enters Collaborative R&D Agreement with Bayer Schering Pharma
6/3/2010